Barinthus Biotherapeutics (BRNS) Competitors

Barinthus Biotherapeutics (NASDAQ:BRNS) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Which has better earnings and valuation, BRNS or ENGN?

enGene has lower revenue, but higher earnings than Barinthus Biotherapeutics. enGene is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	2.40	-$73.35M	-$1.64	-0.54
enGene	N/A	N/A	-$55.14M	-$1.52	-2.76

Is BRNS or ENGN more profitable?

enGene's return on equity of -16.69% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-34.26%	-29.30%
enGene	N/A	-16.69%	-14.27%

Do analysts rate BRNS or ENGN?

Barinthus Biotherapeutics presently has a consensus price target of $5.17, suggesting a potential upside of 480.52%. enGene has a consensus price target of $23.29, suggesting a potential upside of 454.42%. Given Barinthus Biotherapeutics' higher probable upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders & institutionals believe in BRNS or ENGN?

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, BRNS or ENGN?

Barinthus Biotherapeutics has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500.

Does the media favor BRNS or ENGN?

In the previous week, enGene had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 5 mentions for enGene and 4 mentions for Barinthus Biotherapeutics. enGene's average media sentiment score of 1.48 beat Barinthus Biotherapeutics' score of -0.71 indicating that enGene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
enGene	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor BRNS or ENGN?

enGene received 3 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 95.24% of users gave enGene an outperform vote.

Company	Underperform	Outperform
Barinthus Biotherapeutics	Outperform Votes 17 100.00%	Underperform Votes No Votes
enGene	Outperform Votes 20 95.24%	Underperform Votes 1 4.76%

Summary

enGene beats Barinthus Biotherapeutics on 12 of the 16 factors compared between the two stocks.